Thalys Medical stock alerted for trading volatility

Wuhan Thalys Medical Technology (SSE:603716) has announced that its stock experienced abnormal trading volatility, with a cumulative deviation exceeding 20% within three trading days. The company confirmed, following internal verification and inquiries with its controlling shareholder, Saihai (Shanghai) Health Technology, and actual controller, Mr. Wen Wei, that there are no undisclosed material events pending, such as major asset restructuring or equity changes. While operations remain normal, Thalys Medical reported an expected net loss of ¥210 million to ¥250 million for 2024, with a non-recurring loss adjusted net loss of ¥145 million to ¥190 million, noting also risks related to receivables collection and potential delays in repaying maturing raised funds. Investors are advised to be aware of secondary market risks, the potential for continued losses, and the ongoing investigation by the China Securities Regulatory Commission (CSRC) for suspected information disclosure violations.